Given this risk, we thought we'd take a look at whether Dianthus Therapeutics (NASDAQ:DNTH) shareholders should be worried about its cash burn. For the purposes of this article, c ...
Full Year 2024 Results Key Financial Results Net loss: US$85.0m (loss widened ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback